

Market Announcement

2 April 2020

Paradigm Biopharmaceuticals Limited (ASX:PAR) – Trading Halt

Description

The securities of Paradigm Biopharmaceuticals Limited ('PAR') will be placed in trading halt at the request of PAR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 6 April 2020 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Adviser, Listings Compliance (Melbourne)



paradigm
BIOPHARMA

2 April 2020

By email: melissa.kostopoulos@asx.com.au

Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne)
ASX Limited

Dear Melissa

Request for a trading halt

Paradigm Biopharmaceuticals Limited ACN 169 346 963 (ASX: PAR) (the **Company**), requests that the Company's securities be placed into trading halt with immediate effect.

The Company has received an update from the Food & Drug Administration (**FDA**) which it is currently having its regulatory consultants review. Accordingly pursuant to ASX Listing Rule 17.1, the Company requests the trading halt in order to finalise its review and update to the market.

We anticipate that the trading halt will be required until no later than 10am on Monday 6 April 2020. An announcement will be made to the market prior to that time which will clarify the above.

The Company is not aware of any reason why the trading halt should not be granted by the ASX Limited.

Please contact us should you have any questions.

Yours faithfully

Kevin Hollingsworth
Company Secretary
For and on behalf of the Board of Paradigm Biopharmaceuticals Limited

Paradigm BioPharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins Street, Melbourne, VIC, 3000, AUSTRALIA
Web: www.paradigmbiopharma.com